Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAYBREAK study of LY3314814 in mild Alzheimer's disease dementia
NL-OMON47043Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lanabecestat in Alzheimer's disease (AD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog-13) score. Started May 2017; status: recruiting.
02
Drugs
lanabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON47043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47043.